Neuroone Medical Technologies Corporation · NASDAQ:NMTC
Neuroone Medical Technologies — Q2 2025 Earnings Presentation
19 slides from Neuroone Medical Technologies's earnings presentation, May 13, 2025
Slide 1: Corporate Presentation
NASDAQ: NMTC Corporate Presentation May 2025
Slide 2: Forward-Looking Statements
NASDAQ: NMTC Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information con
Slide 3: NeuroOne is a medical technology company transforming diagnosis and treatment of neurological disorders
NASDAQ: NMTC NeuroOne is a medical technology company that is transforming the diagnosis and treatment of neurological disorders FDA- Patented Exclusive Cleared Technology Partnerships 3 FDA 510(k) cleared products for use in the Patented and disruptive Exclusive partnership with brain, with the onl
Slide 4: NeuroOne's next-generation electrode platform is highly disruptive and differentiated
NASDAQ: NMTC NeuroOne’s next-generation electrode platform is highly disruptive and differentiated Since the 1950s, clinicians and researchers have used first generation electrodes for the recording and stimulation of brain tissue. NeuroOne’s multi-purpose electrodes are trying to reduce the number
Slide 5: Mayo Clinic Partnership
NASDAQ: NMTC Mayo Clinic Partnership Current Investor • Mayo Clinic began testing technology in pre-clinical models and clinical research in 2015 • Mayo Clinic leading neurologist, Dr. Worrell, chairs the NeuroOne Scientific Advisory Board • First commercial human use of Evo® Cortical Electrodes per
Slide 6: Zimmer Biomet Partnership
NASDAQ: NMTC Zimmer Biomet Partnership • Zimmer is a worldwide leader in robotic technology used in minimally invasive neurosurgeries • Evo® electrodes are complementary to Zimmer’s ROSA ONE® robotic neurosurgery platform • Partnership initiated in 2020: $5.5 million total paid to NeuroOne under ini
Slide 7: Our electrode platform addresses multi-billion $ and growing market needs
NASDAQ: NMTC Our electrode platform addresses multi-billion $ and growing market needs¹ $1B+ $1B+ $5B+ $10B+ $10B+ $100M $100M $500M+ $3B $0 Epilepsy (Diagnostic Only) Brain Ablation Parkinson’s Spinal Cord Stimulation Drug Delivery (Back Pain) Actual Market Potential Market Size 1. Company data on
Slide 8: Technology Platform
NASDAQ: NMTC Technology Platform 8
Slide 9: Product Portfolio
NASDAQ: NMTC Product Portfolio Product Use Case Status Application Recording brain activity Currently marketed by Evo® Cortical Electrodes Diagnostic Placed on surface of brain Zimmer Biomet Recording brain activity Currently marketed by Evo® sEEG Electrodes Diagnostic Placed Deeper Into the Brain Z
Slide 10: Thin-Film Evo sEEG & Cortical Electrodes
NASDAQ: NMTC Thin-Film Evo® sEEG & Cortical Electrodes Summary • Increased signal clarity /reduced noise design • Cortical device thinner & lighter than competitive devices • sEEG - Better tactile feedback during brain tissue insertion • Both product lines are distributed by Zimmer Biomet Applicatio
Slide 11: OneRF Ablation System for Brain
NASDAQ: NMTC OneRF® Ablation System for Brain sEEG Recently expanded Zimmer Biomet Partnership to distribute system Summary • One procedure for diagnostic and therapeutic expected to Single-Use RF Procedure save time, money and to improve patient outcomes • Temperature-guided ablation provides addit
Slide 12: OneRF Ablation System for Facial Pain (Trigeminal Neuralgia-TN)
NASDAQ: NMTC OneRF® Ablation System for Facial Pain (Trigeminal Neuralgia-TN) Single Use: TNRF Probe In development, recently filed 510(k) submission with the FDA & Cannula Summary • Legacy TN RF ablation has proven clinical efficacy with Single Use: established reimbursement RF Accessories • OneRF
Slide 13: Spinal Cord Percutaneous Paddle Lead
NASDAQ: NMTC Spinal Cord Percutaneous Paddle Lead Summary • Percutaneously placed paddle electrodes for spinal cord stimulation • Able to stimulate broadly and precisely target tissue • Successfully completed initial testing for durability and stimulation for 5-year use for recording and stimulation
Slide 14: sEEG-Based Drug Delivery System
NASDAQ: NMTC sEEG-Based Drug Delivery System Designed to leverage our sEEG platform enabling drug delivery + brain activity recording Pre-Drug Drug Delivery Post-Drug Delivery Delivery Via Cannula Record Brain Inserted Through Activity with sEEG Record Brain sEEG Electrode(s) Electrode(s) Activity w
Slide 15: Our Management Team and Scientific Advisory Board
NASDAQ: NMTC Our Management Team Dave Rosa Ron McClurg Steve Mertens Mark President & Chief Chief Financial Officer Chief Technology Officer Christianson Executive Officer Co-Founder, Business Development Director, Medical Sales Liaison Hijaz Haris Camilo Diaz Botia Evan Goulet Chris Volker Vice-Pre
Slide 16: Financial Overview
NASDAQ: NMTC Financial Overview Capital Position Highlights & Financial Catalysts ($ in millions) • Debt free balance sheet Cash (as of 4/30/25) $9.4 • Decreasing burn rate in FY2025 Debt $0.0 • FY2025 Guidance: • FY 2025 product revenue of $8.0-$10.0M Upfront Licensing Fee Payment $3.0 (132%-190% i
Slide 17: Upcoming Potential Catalysts
NASDAQ: NMTC Upcoming Potential Catalysts • Zimmer Biomet OneRF® Ablation System full launch • OneRF® Trigeminal Nerve Ablation System FDA submission completed in April 2025 o Potential revenue in calendar 2025 for facial pain ablation system • Electrode revenue expected to more than double in FY202
Slide 18: Key Takeaways
NASDAQ: NMTC Key Takeaways Our platform technology of thin film electrode products improve outcomes for patients suffering from neurological disorders The only company with a single device that can perform multiple diagnostic & therapeutic functions such as recording, ablation and stimulation using
Slide 19: Thank you
NASDAQ: NMTC Thank you Dave Rosa Chief Executive Officer ir@nmtc1.com
NeuroOne Medical Technologies — Q2 2025 Earnings Presentation on 6ix